- Gary Burbach appointed to Sight Sciences' Board of Directors, term expires at 2026 Annual Meeting.
- His medtech expertise strengthens Sight Sciences' position in glaucoma and dry eye markets.
- Appointment aligns with strategic shift towards interventional care in eye care markets.
Sight Sciences, Inc. (SGHT, Financial), an innovative eyecare technology company, has announced the appointment of Gerhard (Gary) F. Burbach to its Board of Directors. Burbach will serve as a Class II director, with his term set to conclude at the 2026 Annual Meeting of Stockholders. This appointment was formalized on April 21, 2025.
Gary Burbach is renowned for his extensive experience in the medtech industry, particularly during his tenure as CEO of Thoratec, where he spearheaded the development of mechanical circulatory assist devices. He currently holds positions on the Board of Directors at BWX Technologies (BWXT) and serves as Chairman for Procyrion Inc. Burbach's wealth of experience is expected to enhance Sight Sciences' leadership in surgical glaucoma and assist in market access efforts in the dry eye segment.
This strategic appointment comes at a pivotal time as the glaucoma and dry eye markets are increasingly transitioning towards interventional care, offering substantial growth opportunities for Sight Sciences. The company's focus on innovative, minimally invasive technologies positions it well to capitalize on these evolving market dynamics.
Paul Badawi, Co-founder and CEO of Sight Sciences, expressed enthusiasm about Burbach's inclusion, citing his proven track record in commercial and operational leadership as invaluable to the company's strategic objectives. As Sight Sciences aims to maintain its leading position in surgical glaucoma and expand its market reach in dry eye treatments, Burbach's insights and guidance are expected to drive significant advances.
Burbach himself highlighted the transformative potential of interventional care in eye health and his eagerness to collaborate with Sight Sciences’ executive team to unlock the company's full potential.
